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Background: Ovarian cancer represents the most fatal type of gynecological malignancies. Unfortunately, there are
still no effective targeted treatment strategies for ovarian cancer. Overexpression of CRM1 has been correlated with
poor prognosis of patients with ovarian cancer.
Aim: In this study, we investigated the antitumor effects of a novel reversible inhibitor of CRM1 in ovarian cancer cells.
Methods: The effects of S109 on proliferation was detected by CCK-8, EdU, clonogenic assay. The protein expression
were determined by Western blot. The subcellular localization of RanBP1 was analyzed by immunofluorescence
microscopy assay.
Results: We demonstrated that S109 could induce nuclear accumulation of RanBP1, a canonical biomarker for
CRM1 inhibition. This effect was clearly reversible in the majority of the cells, whereas the inhibitory effect of LMB
could not be reversed. Our data reveal that treatment with S109 results in decrease in proliferation and
colonogenic capacity of ovarian cancer cells by arresting cell cycle. Mechanistically, S109 treatment increase the
expression of the cyclin-dependent kinase inhibitor p21, while it reduced the expression of cell cycle promoting
proteins, Cyclin D1 and Cyclin B. CRM1 level itself was also down-regulated following S109 treatment. Furthermore, the
nuclei of cells incubated with S109 accumulated tumor suppressor proteins (Foxo1, p27 and IκB-α). More importantly,
Cys528 mutation of CRM1 abolished the ability of S109 to block proliferation of ovarian cancer cells.
Conclusions: Together, our study identifies CRM1 as a valid target in ovarian cancer and provides a basis for the
development of S109 in ovarian cancer.
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Ovarian cancer is the most lethal gynecologic cancer and
the fifth most common cause of cancer death in women
[1]. Most of patients are usually detected at advanced
stages, resulting in poor prognoses [2]. Despite many recent
advancements in the field of ovarian cancer therapeutics,
there has been minimal improvement in survival over the
past 30 years. Surgical tumor debulking followed by chemo-
therapy with a combination of platinum-taxane as first line
treatment for ovarian cancer [3]. However, most of patients
will recur with chemotherapeutic-resistant tumors. Thus,
new molecular targeted therapies are urgently needed.* Correspondence: msniu24@126.com
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creativecommons.org/publicdomain/zero/1.0/The pathogenesis of ovarian cancer represents a multi-
step process that involves accumulation of multiple gen-
etic and molecular lesions leading to the selection of a
malignant clone [4]. The activation of the phos-
phatidylinositol 3 kinase (PI3K) pathway is frequently
deregulated in up to 70 % of ovarian cancers through
mechanisms that include amplification of PIK3CA and
AKT or inactivating mutations of PTEN [5, 6]. The onco-
genic activation of MAPK and NF-κB pathway is also as-
sociated with the pathogenesis of ovarian cancer [7, 8].
Unfortunately, despite a sound biological rationale and en-
couraging activity in preclinical models, the inhibitors of
PI3K pathway have little effect in clinical trials [9]. Given
the complexity and redundancy of the signaling network,
development of new therapeutic approaches was needed,
such as targeting multiple pathway simultaneously or
combination with other targeted therapies.distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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such attractive targets for anticancer therapy [10]. More re-
cently, it has been reported that overexpression of CRM1
is correlated with poor prognosis in ovarian cancer [11].
Knockdown of CRM1 expression arrests cell cycle progres-
sion and inhibits the proliferation of ovarian cancer cells
both in vitro and in vivo [12]. CRM1 is a key member of
nuclear transport receptors and recognizes its export car-
gos through specific leucine-rich nuclear export signal
(NES) consensus sequences [13]. CRM1 cargos include
most of tumor suppressor proteins including Foxos, p53,
p21, p27, APC, survivin and inhibitor of κB-α (IκB-α) [14].
Therefore, inhibiting CRM1 can target multiple pathway
simultaneously and is a promising therapeutic target for
ovarian cancer treatment.
An increasing number of compounds have been isolated
or synthesized that inhibit CRM1 [15, 16]. However, most
of them are irreversible inhibitors which have toxicity on
normal cells. Leptomycin B (LMB) is the classic CRM1 in-
hibitor but is not found to be clinically useful due to se-
vere toxicities [17]. This however did not deter the search
for novel compounds, with reduced toxicities that could
target nuclear export. More recently, it has been reported
that SINE compounds are novel semi-reversible inhibitors
of CRM1 to be developed for clinical use. SINE inhibitor
(KPT-330) is generally well tolerated and can be adminis-
tered over prolonged periods in several phase I clinical tri-
als [18]. Therefore, the reversible inhibitor of CRM1
should be safe and well-tolerated in patients.
In this study, we investigated the effect of a novel re-
versible CRM1 inhibitor S109 on ovarian cancer. We
found that S109 suppresses cell proliferation and cell
cycle of ovarian cancer cells by selectively inhibiting
CRM1. Our findings can potentially be translated to-
wards clinical application of S109 against ovarian cancer.
Materials and methods
Cell culture, antibodies and reagents
The human ovarian carcinoma SKOV-3 and OVCAR-3
cells were maintained in RPMI-1640 medium supple-
mented with 10 % fetal bovine serum, 100 U/mL penicillin
and 100 μg/mL streptomycin. S109 was synthetized by
company. Antibodies against Actin, CRM1, RanBP1, IκB-
α and flag tag were obtained from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Antibodies against Foxo1,
p27, p21, Cyclin D1, Cyclin B and Histone-H3 purchased
from Cell Signaling Technology (CST, Beverly, MA).
Alexa 488-conjugated donkey anti-rabbit antibody was
obtained from Invitrogen Life Technology (Invitrogen,
Carlsbad, CA).
Cell viability assay
Cell proliferation was measured by a Cell Counting Kit-8
(CCK8) assay. Briefly, cells were seeded in quadruplicateon 96-well plates and incubated overnight under standard
conditions to allow cell attachment. The cells were then
treated with S109 in concentrations of 0 to 50 μM and in-
cubated for 72 h. The MTT assay was performed by add-
ing 10 μL of CCK8 to each well and incubating at 37 °C
for 4 h. After incubation, the multiwell plates were then
measured at 450 nm using a spectrophotometer.Immunofluorescence microscopy
SKOV-3 cells were seeded onto black optical-bottom 96-
well glass plates and growth overnight. Medium was
removed and replaced with drug-containing medium. Fol-
lowing the indicated treatments, cells were fixed for 20 min
with 4 % formaldehyde in PBS at room temperature. Next,
cell membranes were permeabilized by treatment with
0.3 % Triton X-100 in PBS for 20 min. After blocking with
1 % bovine serum albumin (BSA) in PBS for 1 h, cells were
treated with primary antibodies (1:50 dilution) in blocking
buffer. Fluorescent secondary antibodies anti-rabbit Alexa
488 were used at 1:200 dilution. After washing, cells were
stained with 10 μg/mL DAPI. Photomicrographic images
were acquired and analyzed using a fluorescence micros-
copy and photographed (Olympus, Japan).EdU assay
Cell proliferation was assessed by 5-ethynyl-2′-deoxyuri-
dine (EdU) fluorescence staining using the Cell-Light™ EdU
DNA Cell Proliferation Kit (Ruibo Biotech, Guangzhou,
China) according to the manufacturer’s instructions [19].
The SKOV-3 cells were seeded in 96-well culture plates
and incubated overnight. Then, the cells were treated with
S109 at various concentrations (0, 1, 2, and 4 μM) for 12 h
and incubated with 50 μM EdU for 4 h at 37 °C. Subse-
quently, the cells were fixed with 4 % paraformaldehyde for
15 min and then treated with 0.5 % Triton X-100 for
20 min. Thereafter, the cells were incubated with 100 μL of
1× Apollo® reaction cocktail for 30 min and then stained
with DAPI for 15 min. After washing with phosphate-
buffered saline (PBS) for 3 times, the cells were exam-
ined with fluorescence microscopy and photographed
(Olympus, Japan).Cell clonogenic assay
SKOV-3 cells were seeded in six-well plates (600 cells/
well) and treated with 0.1 % DMSO (vehicle) or S109 (1,
2 and 4 μM) for 12 h. After treatment, the drug-
containing medium was removed and fresh medium was
added to the wells. Medium was changed every 4 days
for 10–14 days to allow for colony formation. Then, the
cells were fixed with 4 % formaldehyde and stained with
0.1 % crystal violet solution. Finally, positive colony for-
mations were manually counted.
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SKOV-3 cells were seeded in six-well plates at a density
of 2 × 106 cells per well and treated with 2 μM S109 for
24 h. After treatment, cells were collected and fixed in
70 % ethanol. Then, cells were washed twice with PBS
and lastly stained with PI solution that contained
50 μg/mL PI and 25 μg/mL Rnase in the dark for
30 min. Subsequently, the cells was assayed on a FACS-
Calibur (Becton-Dickinson) and analyzed by CellQuest
Pro software (Becton-Dickinson).Fig. 1 S109 inhibits ovarian cancer growth and RanBP1 nuclear export. a Stru
by S109. The growth of SKOV-3 cells were cultured with indicated doses of S1
the mean ± SEM of three replicates (*P < 0.05). c S109 reduces expression leve
for 12 h, and the whole cell lysates were analyzed by immunoblotting. d S109
treated with indicated doses of S109 for 12 h, and the whole cell lysates were
Cells were treated with indicated doses of S109 for 2 h. Fixed cells were staineProduction of lentiviral and establishment of stable cell lines
The wild type or C528S mutation human CRM1 were
cloned into a pWPXL lentiviral vector containing a se-
quence coding for a flag tag. The construct overexpress
lentiviral vectors were co-transfected with pSPXA2 and
pMD2.G plasmids into 293FT packaging cells using lipo-
fectamine 2000 (Invitrogen). After 48 h incubation, the
supernatant was collected and concentrated via ultracentri-
fugation. SKOV-3 cells were seeded into six-well plates and
infected by CRM1-WT or CRM1-C528S lentivirals,cture of S109. b Suppression of the cell of growth of ovarian cancer cells
09 for 72 h and analyzed by the CCK-8 assay. All data are presented as
l of CRM1 protein. SKOV-3 cells were treated with indicated doses of S109
reduces expression level of CRM1 protein in OVCAR cells. Cells were
analyzed by immunoblotting. e S109 inhibits nuclear export of RanBP1.
d for RanBP1 and DAPI and analyzed by fluorescence microscopy
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ously cultured in medium containing 2.5 μg/mL puro-
mycin. The surviving cells were cultured into cell lines
stably expressing CRM1-WT or CRM1-C528S.
Western blotting
The whole or nuclear cell extract of control and treated
cells were used in Western blot analysis [20]. The protein
extracts were resolved by SDS-PAGE. After electrophor-
esis, proteins were electrotransferred to nitrocellulose
membranes. The membrane was blocked and incubated
with relevant antibodies. The proteins then were detected
by enhanced chemiluminescence on X-ray film with an
ECL Western blotting detection kit (Amersham).
Data analysis
Data are means and standard deviations of three inde-
pendent experiments with three to five replicates each.
The results were statistical analyzed using a Student’s t test
and considered statistically significant at the p < 0.05 level.
Results
Novel nuclear export inhibitor S109 suppresses CRM1
function in ovarian cancer cells
We have previously designed S109 as a new inhibitor of
CRM1 (Fig. 1a). To investigate whether S109 is able to
functionally inactivate CRM1 in ovarian cancer cells, weFig. 2 The inhibitory effects of nuclear export by S109 is reversible. a S109
with indicated doses of S109 or LMB for 2 h. Fixed cells were stained for Ra
effect of S109 on the localization of RanBP1. Cells were incubated with ind
and fresh medium was added. Cells were incubated for 1 h and then analyanalyzed the subcellular localization of CRM1 cargo pro-
tein RanBP1, which is a canonical biomarker for CRM1
inhibition. As shown in Fig. 1e, RanBP1 is found exclu-
sively in the cytosol in control cells. In contrast, treat-
ment with S109 only 2 h led to a clear and rapid shift of
RanBP1 to nucleus in a dose dependent manner. Next,
the effect of S109 on the expression level of CMR1 pro-
tein in SKOV-3 and OVCAR-3 cells was analyzed. The
level of CRM1 protein expression became markedly re-
duced in a dose-dependent manner on treatment with
S109 (Fig. 1c and d). In order to investigate the effect of
S109 on cell growth, we evaluated the cell viability of
SKOV-3 cells treated with S109 for 72 h using the CCK-
8 assay. As shown in Fig. 1b, S109 inhibits cell growth in
a dose dependent manner. Notably, the cellular activities
of S109 are consistent with their abilities to suppress nu-
clear export.
The inhibitory effect of S109 is reversible
We investigated whether the inhibition of CMR1 by
S109 could be restored upon removal of the compound.
Therefore, we incubated SKOV-3 cells with LMB or
S109 for 2 h. In cells incubated with S109 or LMB, most
of RanBP1 shifted from a cytoplasmic localization to nu-
cleus, whereas in untreated cells, RanBP1 was still in the
cytoplasm (Fig. 2a). Then, the cells were washed with PBS
to remove the S109 or LMB, and new medium was added.and LMB inhibit nuclear export of RanBP1. SKOV-3 Cells were treated
nBP1 and DAPI and analyzed by fluorescence microscopy. b Reversible
icated doses of S109 or LMB. After 2 h, the drugs were washed out
zed by fluorescence microscopy
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localization by fluorescence microscopy. RanBP1 in cells
incubated with S109 was almost completely translocated
to the cytoplasm, whereas in cells incubated with LMB,
RanBP1 still localized in the nucleus of the cells (Fig. 2b).
Therefore, in contrast to LMB-treated cells, the majority
of S109-treated cells were able to reverse completely the
inhibitory effects of the drug.S109 inhibits the proliferation and colony formation of
SKOV-3 cells
To further confirm the effects of S109 on cell prolifera-
tion, EdU fluorescence staining and clonogenic assays
were performed. S109 treatment resulted in a significant
reduction of the mean percentage of positive prolifera-
tive cells compared with control group (Fig. 3a and b).Fig. 3 S109 inhibits proliferation and colony formation of SKOV-3 cells. a R
Quantitativeresults of EdU incorporation assay. c S109 inhibits the colony fo
The percentage of proliferative cells or colony formation were normalized
in three repeats (*P < 0.05)At 2 μM of S109, the proliferation was reduced to about
50.6 %. Since CCK-8 and EdU assay is a short term assay
for proliferation and does not effectively convey cell sur-
vival, we performed a cell survival clonogenic assay to
evaluate the long term effect of CRM1 inhibition. Figure 3c
and d also show a dose dependent inhibition of clonogenic
potential by S109 in SKOV-3 cells. The results from the
clonogenic assay were consistent with the CKK-8 and EdU
assay data shown suggesting that S109 inhibited cell
growth in ovarian cells.
S109 induces cell cycle arrest through nuclear localization
of tumor suppressor proteins
In order to verify whether S109 works by abrogating cell
cycle progression, propidium iodide flow cytometry as-
says were performed. SKOV-3 cells were exposed to
2 μM of S109 for 24 h and analyzed for cell cycleepresentative EdU analysis of cell proliferation after S109 treatment. b
rmation of SKOV-3 cells. d Quantitative results of clonogenic assay.
to that of the control group. All the data are presented as mean ± SEM
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rest at G1 phase in response to treatment with S109 as
shown by an increase in the G1fraction from 51.9 % in
the control cells to 79.7 % in S109-treated cells (Fig. 4a).
A concomitant decrease in the percentage of S109-
treated cells with respect to controls in S phase was ob-
served. However, there were no significant effect of S109
treatment on the apoptosis of SKOV-3 cells (data not
show). Together, these data demonstrate that the anti-
proliferation effects of S109 treatment are due to indu-
cing cell cycle arrest, and not induction of apoptosis.
In order to delineate the molecular mechanisms of
ovarian cancer cell cycle arrest induction by S109 in
greater detail, the expression and nuclear localization of
tumor suppressor proteins was investigated using west-
ern blot analysis. First, we measured the protein expres-
sion levels of cell cycle regulators after treatment with
S109 by Western blotting with respect to the controls
(Fig. 4b). Strikingly, we found a strong up-regulation ofFig. 4 S109 induces cell cycle arrest and nuclear retention of tumor suppre
Cells were harvested, stained with propidium iodide and analyzed by flow
concentrations for 24 h. Cells were then harvested and subjected to immu
concentrations for 24 h. Nuclear proteins was extracted and subjected to im
indicated concentrations for 24 h. Nuclear proteins was extracted and subjtumor-suppressor protein p27 in SKOV-3 cells upon
treatment with S109. Furthermore, the expression of
proliferative proteins Cyclin D1 and Cyclin B were
downregulated in a dose-dependent manner after treat-
ment with S109. Next, we investigated the effects of
S109 on the nuclear accumulation of tumor suppressor
proteins in ovarian cancer cells. As shown in Fig. 4c and
d, exposure of SKOV-3 and OVCAR-3 cells to increas-
ing concentrations of S109 resulted in a progressive in-
crease in the nuclear fraction of major tumor suppressor
proteins (Foxo1, p27 and IκB-α). Together, these data in-
dicate that S109-induced cell cycle arrest is associated
with downregulation of proliferative proteins and nu-
clear accumulation of tumor suppressor proteins.
Mutation of CRM1 abolishes S109 cytotoxicity in ovarian
cancer cells
LMB, the very potent inhibitor of CRM1, selectively binds
to Cys528 of CRM1 [21]. To investigate whether thessor proteins. a SKOV-3 cells were exposed to 2 μM of S109 for 24 h.
cytometry. b SKOV-3 cells were treated with S109 at the indicated
noblot analysis. c SKOV-3 cells were treated with S109 at the indicated
munoblot analysis. d OVCAR-3 cells were treated with S109 at the
ected to immunoblot analysis
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Cys528 of CRM1, we have prepared SKOV-3 cells stable
expressing a wild type or C528S mutant CRM1. First,
overexpression of wild or mutant type CRM1 did not alter
the expression levels of CRM1 (Fig. 5a). However, in
CRM1-C528S expressing SKOV-3 cells, exposure to S109
did not induce significant nuclear accumulation of tumor
suppressor proteins, Foxo1 and p27 (Fig. 5b). Next, we an-
alyzed the effect of S109 on the level of wild type or mu-
tant CMR1 expression. As shown in Fig. 5c, cells
expressing CRM1-C528S were resistant to S109, as CRM1
expression level did not show significant decrease even at
high concentrations of S109.
We further evaluated whether S109 loses its ability to
inhibit the proliferation of CRM1-C528S expressing cells.
Consistent with our previous results, S109 treatment re-
sulted in a significant growth inhibition at 1, 2 and 4 μM
concentrations in CRM1-WT expressing cells. However,
in CRM1-C528S expressing SKOV-3 cells, exposure toFig. 5 Cys528 mutation of CRM1 abolished the ability of S109 to inhibit prolif
expressing wild type or C528S mutant CRM1. Western blot analyses the expre
SKOV-3 cells were treated with S109 at the indicated concentrations for 24 h.
Wild type and C528S mutant SKOV-3 cells treated with indicated doses of S10
Growth inhibition assay in wild type and C528S mutant cells. Cells were seede
for 72 h. Growth inhibition was analyzed by the CCK-8 assay. All the data are pS109 did not induce significant growth inhibition at the
same concentrations (Fig. 5d). Thus, based on these ex-
perimental observations, we have determined that the an-
ticancer effects of S109 are dependent on binding to the
Cys528 of CRM1.
Discussion
Ovarian cancer is the most fatal among gynecololgic
cancers [22]. Until now, however, there are no effective
targeted treatment strategies for ovarian cancer. There is
an urgent need for newer and more effective drugs for
ovarian cancer treatment. In this report we show the anti-
cancer potential of a novel small molecule CRM1 inhibitor
S109 in ovarian cancer. S109 inhibits CRM1-dependent
nuclear export, causing arrest of the cell cycle, inhibiting
proliferation and suppressing clonogenic potential of ovar-
ian cancer cells.
Recently, it has been reported that overexpression of
CRM1 is correlated with poor prognosis in ovarian cancereration. a Whole cell lysates were extracted from the cells stable
ssion level of CRM1 in both SKOV-3 cells. b Wild type and C528S mutant
Nuclear proteins was extracted and subjected to immunoblot analysis. c
9 for 12 h. The whole cell lysates were analyzed by immunoblotting. d
d in 96-well plates and incubated with S109 at indiated concentrations
resented as mean ± SEM in three repeats (*P < 0.05)
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or expressed at supraphysiogic levels within cancer cells
[23]. CRM1 overexpression results in constitutive nuclear
export of tumor suppressor proteins thereby facilitating
proliferation [24]. Inhibition of nucleo-cytoplasmic trans-
port by natural and synthetic compounds has been pursued
as a therapeutic avenue in cancer based on a number of
biologic observations [18]. Therefore, targeted inhibition of
CRM1 is an attractive strategy against ovarian cancer.
Several CRM1 inhibitors have been described, how-
ever, most of them are irreversible inhibitors. We dem-
onstrated that S109 could induce nuclear accumulation
of RanBP1, a canonical biomarker for CRM1 inhibition.
This effect was clearly and quickly reversible in the ma-
jority of the cells, whereas the inhibitory effect of LMB
could not be reversed. These results indicate that S109 is
a reversible CRM1 inhibitor in ovarian cancer cells. We
also found that S109 reduced CRM1 protein levels in
ovarian cancer cells. However, the irreversible inhibitor
LMB could not induce decrease of CRM1 [25]. Most of
CRM1 inhibitors have antitumor effects without affect-
ing the protein level of CRM1. The antitumor effects of
S109 may be not due to the inhibition of CRM1 down-
regulation by S109. We argued that although reversible
inhibitors bind to the same residue in CRM1 as LMB,
reversible inhibitors can likely change the conformation
of CRM1 such that it is recognized by the proteasomal
degradation machinery and thereby degraded.
The PI3K/Akt pathway plays an important part in the
regulation of multiple biological processes, including
apoptosis, metabolism, cell proliferation and cell growth
[26]. It is one of the pathways most frequently targeted
by genomic aberrations in ovarian cancer. There is
growing evidence that genetic degergulation of key com-
ponents of the PI3K/Akt pathway results in the activa-
tion of downstream signaling pathways, including Foxo1,
Cyclin D1, Bad and NF-κB [27]. These Akt pathway
components might be therapeutic targets and important
mediators of resistance to other targeted therapies. Thus,
a therapeutic strategy simultaneously targeting multiple
oncogenic pathways or targets might be a rational and
effective strategy in ovarian cancer. CRM1 inhibitors can
target multiple oncogenic pathways simultaneously [18].
We found that S109 could downregulate the expression
of Cyclin D1 and Cyclin B, and induce nuclear retention
of major tumor suppressor proteins (Foxo1, p27 and
IκB-α). These tumor suppressor proteins play important
roles in Akt, NF-κB and cell cycle pathway, respectively.
Cytoplasmic Foxo1 has been shown to be particularly
high expression both in paclitaxel-resistant ovarian cancer
cell lines and clinical samples [28]. In contrast, nuclear
Foxo1 is a favorable factor and induced by paclitaxel treat-
ment. Foxo1 could be a molecular target for the treatment
of sensitive or drug-resistant ovarian cancers. Our datademonstrated that S109 could lead to retention of Foxo1
in the nucleus, contributing to cell cycle arrest. Our results
suggest that foxo1 is an important component of the
downstream signaling pathway of CRM1 inhibition in
ovarian cancer cells.
The present study shows for the first time that S109
has prominent antitumor activity against ovarian cancer
cells. S109 reduced levels of CRM1 protein and inhibited
cell proliferation. In particular, we have provide strong
evidence in support of a S109 mechanism of action that
involves nuclear retention of different tumor suppressor
proteins, especially Foxo1. Together, our study identifies
CRM1 as a novel target in ovarian cancer and demon-
strates that S109 can act as potent agents for ovarian
cancer treatment.
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